程序性死亡受体1抑制剂卡瑞利珠单抗联合化疗治疗晚期食管鳞状细胞癌的临床疗效

Clinical efficacy of programmed cell death 1 inhibitor camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma

目的探讨程序性死亡受体1(PD-1)抑制剂卡瑞利珠单抗联合化疗治疗晚期食管鳞状细胞癌的临床疗效。方法根据治疗方式的不同将102例晚期食管鳞状细胞癌患者分为对照组和观察组,每组51例,对照组患者给予多西他赛化疗,观察组患者给予多西他赛联合卡瑞利珠单抗治疗。比较两组患者的临床疗效、生活质量、不良反应和预后情况。结果治疗后,观察组患者的客观缓解率为17.65%,与对照组患者的13.73%无明显差异(P﹥0.05);观察组患者的疾病控制率为88.24%,明显高于对照组患者的58.82%,差异有统计学意(P﹤0.01)。治疗后,两组患者欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)各维度评分均高于本组治疗前,且观察组患者EORTC QLQ-C30量表各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者甲状腺功能减退、发热、胃肠道反应、贫血、乏力、高脂血症、肝功能损伤、皮肤不良反应、心脏毒性发生率比较,差异均无统计学意义(P﹥0.05)。对照组患者的中位无进展生存期(PFS)为4.9个月(95%CI:2.4~7.8),明显短于观察组患者的7.1个月(95%CI:4.3~9.9),差异有统计学意(P﹤0.01)。结论PD-1抑制剂卡瑞利珠单抗联合化疗治疗晚期食管鳞状细胞癌有一定的临床疗效,特别是对疾病控制有积极意义,且不会加重患者的不良反应,有助于提高患者的生活质量。

Objective To investigate the clinical efficacy of programmed cell death 1(PD-1)inhibitor camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma.Method A total of 102 patients with advanced esophageal squamous cell carcinoma were divided into control group(n=51,treated with docetaxel chemotherapy)and observation group(n=51,treated with camrelizumab+docetaxel)according to treatment methods.The clinical efficacy,quality of life,adverse reaction and prognosis were compared between the two groups.Result After treatment,the objective remission rate of patients in the observation group was 17.65%,which was no significant difference from 13.73%of patients in the control group(P>0.05).The disease control rate of patients in the observation group was 88.24%,which was significantly higher than 58.82%of patients in the control group(P<0.01).After treatment,the scores of European Organization for Research and Treatment of Cancer quality of life questionnaire core-30(EORTC QLQ-C30)in both groups were higher than those before treatment,and the scores of EORTC QLQ-C30 in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences between the two groups in the incidence of hypothyroidism,fever,gastrointestinal reaction,anemia,fatigue,hyperlipidemia,liver function injury,skin adverse reaction and cardiotoxicity(P>0.05).The median progression-free survival(PFS)in the control group was 4.9 months(95%CI:2.4-7.8),which was significantly shorter than 7.1 months(95%CI:4.3-9.9)in the observation group,the difference was statistically significant(P<0.01).Conclusion PD-1 inhibitor camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma has a certain clinical efficacy,especially has a positive significance for disease control,and will not aggravate the adverse reactions of patients,which is helpful to improve the quality of life of patients.